Major Stock Offering Announced by 89bio, Inc.
89bio, Inc. (NASDAQ: ETNB), a pioneering clinical-stage biopharmaceutical firm, focuses on crafting and marketing advanced therapies targeting liver and cardiometabolic diseases. The company has recently updated the market regarding its public offering, amassing an impressive $125 million.
Details of the Public Offering
This upsized underwritten public offering includes 11,455,882 shares of 89bio's common stock, each priced at $8.50. Additionally, certain investors will receive pre-funded warrants enabling them to purchase up to 3,250,000 shares at a price of $8.499.
Warrants and Underwriters
The pre-funded warrants come with an exercise price of just $0.001 per share, and they can be exercised immediately. The underwriters also have a 30-day option to acquire an extra 2,205,882 shares, allowing for potential further fundraising.
Financial Expectations from the Offering
89bio anticipates generating approximately $125 million from this offering, which will significantly support its current and future therapeutic developments. The close of the offering is projected around mid-November, contingent upon meeting customary closing conditions.
Role of Underwriters in the Offering
In this venture, Goldman Sachs & Co. LLC, Leerink Partners, and Evercore ISI are designated as the book-running managers. Their expertise will be instrumental in ensuring that the offering goes smoothly and meets the anticipated financial goals.
Compliance and Regulatory Framework
89bio has filed an automatically effective shelf registration statement with the Securities and Exchange Commission (SEC), which covers the securities being offered. This approach ensures compliance and allows for a seamless public offering process.
About 89bio's Innovative Therapies
89bio is committed to creating effective treatments for patients suffering from liver conditions that lack adequate alternatives. Currently, they are advancing their lead candidate, pegozafermin, through Phase 3 clinical trials aimed at addressing metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
Technology Behind Pegozafermin
Pegozafermin features a specially designed analog of fibroblast growth factor 21, enhanced through unique glycoPEGylated technology. This development aims to improve its biological activity and extend its half-life, thereby offering potential breakthroughs in treatment.
Contact Information for Stakeholder Inquiries
For additional inquiries regarding this offering or company details, interested parties can reach out to Annie Chang at 89bio, Inc., or alternatively, to LifeSci Advisors, LLC, which is ready to assist with investor relations.
Frequently Asked Questions
What is the purpose of the public offering by 89bio, Inc.?
The primary goal is to raise funds to support the development of innovative therapies for liver and cardiometabolic diseases.
How much capital is 89bio looking to raise?
89bio aims to raise approximately $125 million through this public offering.
What are the financial instruments involved in this offering?
The offering includes common stock shares and pre-funded warrants to enable investors to acquire 89bio's common stock.
Who are the underwriters for this public offering?
Goldman Sachs & Co. LLC, Leerink Partners, and Evercore ISI are serving as the book-running managers for this offering.
What is the status of 89bio's lead candidate?
Pegozafermin is currently in Phase 3 clinical trials, showcasing the company's commitment to developing effective treatments for specific liver conditions.
